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Support for involvement of the AHI1 locus in
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Recently, markers in the Abelson Helper Integration Site 1 (AHI1) region were shown to be associated with
schizophrenia in a family sample of Israeli-Arabs. Here, we report a study evaluating the relevance of the
AHI1 region to schizophrenia in an Icelandic sample. Seven markers shown to confer risk in the previous
report were typed in 608 patients diagnosed with broad schizophrenia and 1504 controls. Odds ratios for
the overtransmitted alleles in the Israeli-Arab families ranged from 1.15 to 1.29 in the Icelandic sample.
After Bonferroni correction for the seven markers tested, two markers were significantly associated with
schizophrenia. Thus, our results are in general agreement with the previous report, with the strongest
association signal observed in a region upstream of the AHI1 gene.
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Introduction
The pathogenesis of schizophrenia involves complex
interaction of genetic variants and environmental factors.1
Several susceptibility loci for schizophrenia have been
identified using linkage analysis, and a recent meta-
analysis showed greater consistency across studies than
previously had been recognized.2 Linkage to chromosome
6q is seen in several studies3 – 5 and although extensive
genomic distance is implicated in the different reports, a
6q15-23.2 locus is supported by meta-analysis.2 A recently
published analysis of inbred schizophrenia pedigrees of
Israeli-Arab origin lends further support to the linkage on
6q, with a peak marker at 6q23.3.6,7 Subsequent family-
based association study of the same pedigrees, using SNP
markers from the 6q23.3 locus, revealed significant
association of markers in a linkage disequilibrium (LD)
block harbouring the Abelson Helper Integration Site 1
(AHI1) gene.8 The AHI1 gene is expressed at high levels in
both foetal and adult human brain.9 Mutations in the gene
have been shown to cause Joubert Syndrome, an autosomal
recessive brain disorder.10
In the association analysis by Amann-Zalcenstein et al,8
seven SNP markers were significant at single marker level
after Bonferroni correction in the original linkage sample.
The same seven markers have now been typed on a large
sample of Icelandic schizophrenia patients and controls.
Subjects and methods
Human samples
Approval for the study was granted by the National
Bioethics Committee of Iceland and the Icelandic Data
Protection Authority and informed consent was obtained
for all participants. For this study, 608 patients with a
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broad schizophrenia diagnosis (schizophrenia (N¼574),
schizoaffective disorder (N¼25), schizotypal features
(N¼ 6), unspecified functional psychosis (N¼3)) were
identified through referrals to in- and outpatient services.
Diagnoses were assigned according to the Research Diag-
nostic Criteria (RDC)11 through the use of the lifetime
version of the Schizophrenia and Affective Disorders
Schedule (SADS-L).12 Two groups of controls were used:
one set (N¼1045) was chosen randomly from the Icelandic
population; a second group (N¼459) was recruited from
longevous Icelanders aged 90 years and older. Demo-
graphic and relatedness information for cases and both
sets of controls is shown in Supplementary Table 1. Neither
control group was screened specifically for the presence of
psychiatric illnesses.
Genotyping and statistical analysis
DNA was isolated from whole blood or lymphoblastoid cell
lines using an extraction column method (Qiagen Inc.,
Valencia, CA, USA) and SNP genotyping was carried out
using the Centaurus platform (Nanogen Inc., San Diego,
CA, USA). Owing to assay failure, markers with r2¼1 in the
CEU Hapmap sample were chosen as surrogates for two of
the original markers. Average marker yield was 95.7% (see
Supplementary Tables 2 and 3 for additional information
on yield) and no significant deviation from Hardy–
Weinberg equilibrium was detected in controls (see
Supplementary Table 4 for more information on Hardy–
Weinberg equilibrium).
To test the hypothesis that the at-risk alleles identified by
Amann-Zalcenstein et al8 were found at elevated frequen-
cies in Icelandic schizophrenics, the signed square-root of a
standard likelihood ratio test statistic was used to calculate
one-sided P-values. Partial information about missing
genotypes, available because the seven markers were in
LD, was also incorporated into the test statistic using a
likelihood approach implemented in the program
NEMO.13 Inclusion of this partial information allowed
findings for each marker to be based on the same set of
individuals and, therefore, to be more comparable. Results
incorporating this partial information were not substan-
tially different from those arrived at using information
from only a single marker. Haplotype analyses were carried
out using a likelihood procedure in NEMO as described in
an earlier publication.14
The likelihood ratio test statistic discussed above was
computed without taking the relationships both between
and within the affected and control groups into account.
This was adjusted for by using the Icelandic genealogy to
carry out one million simulations of the test statistic under
the null hypothesis of no allele frequency difference
between cases and controls. The variance of this empirical
null distribution was then used in the calculation of P-
values. See Grant et al15 for further details.
Results
Single marker association results are summarized in Table 1.
As there were no significant differences between the two
control groups (not shown), results are presented for the
combined control group only.
For the overtransmitted alleles in the study of Amann-
Zalcenstein et al,8 odds ratios (ORs) ranged from 1.15 to
1.29 in the Icelandic sample. For all seven markers, P-
values wereo0.05, and for two markers, the difference was
significant after Bonferroni correction for seven tests.
Five of the seven markers were also used for haplotype
association (rs11154801 and rs9647635 were not included
as they were nearly equivalent to rs7750586). For 138
haplotypes made up of two to five markers and with
frequencies of at least 1%, no association to schizophrenia
notably stronger than that found in single-marker analyses
was observed (Supplementary Table 5).
The LD structure of the AHI1 locus in the CEU Hapmap
sample is depicted in Figure 1 along with known gene
structures and human mRNAs in the region as annotated
in the UCSC browser, using Build 36 sequence. The
C6orf217 record has been discontinued since the publication
Table 1 Allelic association to schizophrenia for the seven tested markers in 608 patients and 1504 controls
Marker Allelea Allelic P-value ORb Affected frequency Control frequency
rs9321501 A 0.017 1.17 (1.01–1.35) 0.553 0.515
rs11154801 C 0.037 1.15 (0.99–1.33) 0.679 0.649
rs7750586 A 0.030 1.15 (0.99–1.34) 0.680 0.648
rs9647635 A 0.038 1.15 (0.99–1.33) 0.678 0.647
rs7739635 C 0.0032 1.24 (1.06–1.44) 0.702 0.656
rs9494335, surrogate for A-rs9494332 (r2¼1.0c) A 0.012 1.20 (1.03–1.40) 0.716 0.678
rs9399158, surrogate for A-rs1475069 (r2¼1.0c) C 0.00076 1.29 (1.10–1.52) 0.743 0.691
P-values are one-sided and corrected for relatedness between subjects but not for number of tests. Owing to assay failure, perfect proxy markers were
chosen for two of the original markers, based on Hapmap genotype data for the CEU sample. Allelic P-values that remain significant after Bonferroni
correction are indicated in bold print.
aOvertransmitted in Amann-Zalcenstein et al.8
bAllelic odds ratio assuming a multiplicative model with 95% confidence interval.
cIn the CEU Hapmap sample.
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of Amann-Zalcenstein et al,8 and the hypothalamic mRNA,
BC040979, now inhabits the region immediately upstream
of the AHI1 gene. Although markers are in LD throughout
the locus, three substructures of stronger LD are observed.
Pairwise correlation between the markers in the Icelandic
data set is summarized in Supplementary Figure 1, and
shows a pattern consistent with the CEU Hapmap LD
structure. No significant differences in LD were seen
between patients and controls (data not shown).
Discussion
Studying an inbred population, Amann-Zalcenstein et al
were able, by following linkage analysis with family-based
association, to identify seven markers strongly associating
with schizophrenia.8 The association was found in an LD
block, spanning Mb 135.667–136.179 (NCBI Build 36) on
chromosome 6 harbouring the AHI1 gene. We found all
seven significantly overtransmitted alleles from their study
in higher frequency in Icelandic schizophrenics than in
controls (Table 1). In the Icelandic sample, the ORs for
the tested alleles ranged from 1.15 to 1.29, and two of the
markers remained significantly associated to schizophrenia
after Bonferroni correction for seven tests. The two
significant markers, rs7739635 (P¼0.0032, RR¼1.24) and
rs9399158, a perfect proxy for rs1475069, (P¼0.00076,
RR¼1.29) are located in a substructure of the large LD
block containing the AHI1 gene (Figure 1). This substruc-
ture, spanning Mb 135.954–136.179, is upstream of the
AHI1 gene and contains one uncharacterized mRNA
isolated from hypothalamus, and may contain regulatory
elements for both the AHI1 and phosphodiesterase 7B
(PDE7B) genes. Thus, although our findings are in line with
the previous report, the strongest association signal is
observed in a substructure of the large LD block initially
implicated in the disease.
The AHI1 gene has already been pointed out as a
plausible schizophrenia susceptibility gene at this locus.
The BC040979 transcript is a candidate as well; however, it
needs further characterization. Finally, the PDE7B gene
encodes a cAMP-specific phosphodiesterase, thought to be
involved in neuronal cAMP regulation.16,17 Although not
in LD with the significant markers, PDE7B should not be
ruled out as a candidate, as the region showing significant
association is upstream of PDE7B and therefore may
contain regulatory elements for the gene.
In summary, we have presented results from a case–
control association analysis that are in line with data
presented by Amann-Zalcenstein et al,8 showing that the
AHI1 locus contributes to schizophrenia. Still, three
neighbouring genes, AHI1, BC040979 and PDE7B can be
affected by variants in this region and none of these genes
can be excluded.
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